TM38837

TM-38837

TM-38837

Chemical compound

TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma.[1] The company has announced phase I clinical trials.

Quick Facts Clinical data, ATC code ...

TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.[2]

See also

References

  1. [1]
    "7TM Pharma". Archived from the original on July 7, 2011. Retrieved January 18, 2011.
  2. [2]
    Hung MS, Chang CP, Li TC, Yeh TK, Song JS, Lin Y, et al. (September 2010). "Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist". ChemMedChem. 5 (9): 1439–43. doi:10.1002/cmdc.201000246. PMID 20652930. S2CID 34244587.
Stub icon

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article TM38837, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.